Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Purchases 314,870 Shares of Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 314,870 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was bought at an average cost of $17.36 per share, with a total value of $5,466,143.20. Following the purchase, the director owned 17,672,676 shares of the company’s stock, valued at approximately $306,797,655.36. This trade represents a 1.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Burning Rock Biotech Price Performance

Shares of BNR opened at $16.20 on Friday. The business has a 50-day moving average of $25.63 and a 200-day moving average of $19.39. The company has a market capitalization of $174.31 million, a price-to-earnings ratio of -20.51 and a beta of 1.59. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $2.18 and a 1 year high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Saturday, February 14th. The company reported ($0.21) earnings per share for the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%. The firm had revenue of $18.05 million for the quarter.

Institutional Trading of Burning Rock Biotech

Large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Burning Rock Biotech in the 3rd quarter valued at $26,000. Prospera Financial Services Inc acquired a new stake in Burning Rock Biotech in the third quarter worth $214,000. Marshall Wace LLP acquired a new stake in Burning Rock Biotech in the fourth quarter worth $220,000. Finally, Crcm LP increased its stake in Burning Rock Biotech by 13.8% in the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares in the last quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.

Analyst Ratings Changes

BNR has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Wednesday, January 21st. Wall Street Zen upgraded Burning Rock Biotech from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.